James Kew Editor

James Kew received a degree in Biological Sciences from Exeter University in 1991 and a Ph.D. from Cambridge University in 1995. He joined F.Hoffmann-La Roche in Basel in 1995, first as a postdoctoral scientist and subsequently as head of an electrophysiology and cell biology laboratory. During this period his work focussed on the pharmacology, physiology/pathophysiology and therapeutic potential of both ionotropic and metabotropic glutamate receptors and their ligands. He joined GlaxoSmithKline in 1995 as Head of Electrophysiology in the Psychiatry CEDD before moving to head the newly formed Psychiatry Discovery Technology Group in October 2006. Since October 2008 he has led the Molecular and Cellular Biology group within the Schizophrenia and Cognitive Disorders Discovery Performance Unit in the Neurosciences CEDD. Ceri Davies received BSc (Hons) and Ph.D. degrees in Pharmacology from Bristol University in 1988 and 1991. He held a Lectureship in Neuropharmacology at the University of Edinburgh until 1998 when he moved into the pharmaceutical industry running an electrophysiology team at Organon laboratories near Glasgow. During this appointment his work focussed on developing novel approaches to treat psychiatric disorders. He joined GlaxoSmithKline a year later as Head of Electrophysiology in the Neurology and Gastrointestinal Centre for Excellence in Drug Discovery (CEDD) before moving to head up the Neuropharmacology and Physiology department in the Psychiatry CEDD in 2003. Since May 2008 he has led the Synaptic Plasticity and Neural Networks Discovery Performance Unit within the newly formed Neurosciences CEDD.